Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.83+0.30 (+1.05%)
Close on Nov 13, 2026Market cap $2.26BP/E –Yield –
Celldex Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Celldex Therapeutics's enterprise value was $1.65B on Nov 11, 2026, against $1.21B a year earlier. Over the last 5 years it ranged from $479.42M to $2.39B, with a median of $1.22B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.65B | +35.0% |
| 2025 | Dec 31, 2025 | $1.22B | +32.7% |
| 2024 | Dec 31, 2024 | $920.52M | -43.8% |
| 2023 | Dec 29, 2023 | $1.64B | -7.7% |
| 2022 | Dec 30, 2022 | $1.78B | +28.7% |
| 2021 | Dec 31, 2021 | $1.38B | +179.6% |
| 2020 | Dec 31, 2020 | $493.54M | – |
| 2019 | Dec 31, 2019 | -$37.45M | – |
| 2018 | Dec 31, 2018 | -$71.90M | -130.6% |
| 2017 | Dec 29, 2017 | $234.64M | +51.2% |
| 2016 | Dec 30, 2016 | $155.15M | -87.5% |
| 2015 | Dec 31, 2015 | $1.24B | -11.8% |
| 2014 | Dec 31, 2014 | $1.41B | -22.9% |
| 2013 | Dec 31, 2013 | $1.83B | +453.0% |
| 2012 | Dec 31, 2012 | $330.40M | +535.3% |
| 2011 | Dec 30, 2011 | $52.01M | +110.8% |
| 2010 | Dec 31, 2010 | $24.67M | – |
See a number that looks wrong?